Journal of anesthesia
-
Journal of anesthesia · Aug 2022
Letter Multicenter StudyCharacteristics of COVID-19 in multicenter ICUs in Japan.
-
Journal of anesthesia · Aug 2022
A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice.
Remimazolam besylate is a novel short-acting benzodiazepine. An appropriate pharmacokinetic model of remimazolam is desirable in anesthesia practice. The aim of the study was to develop a pharmacokinetic model using plasma samples from patients anesthetized with remimazolam. Influence of patient characteristics, context-sensitive decrement-times, and dose regimens were also examined. ⋯ Remimazolam pharmacokinetic model for general anesthesia was successfully developed. ABW, ASA-PS, and sex has a considerable impact on the remimazolam concentration.